Sharekhan's research report on Dr. Reddy’s Laboratories
For Q4FY23, Dr. Reddy’s Laboratories’ (DRL’s) profitability was augmented by proceeds from divestment of a few non-core brands amounting to Rs. 494.1 crore; this was included in reported revenue. Normalized net income rose ~27.9% y-o-y to ~ Rs. 550 crore, excluding brand divestment-related income, while reported net profits increased ~ 889.8% y-o-y to Rs. 960.1 crore in Q4FY23. Core EBITDA margins excluding other non-operating income and unusual gains and impairment costs fell by ~ 165 bps y-o-y to ~ 18.8% in Q4FY23. Reported EBITDA margins rose ~ 156 bps y-o-y to 25.1%.
Outlook
Stock trades at ~ 15.3x/14.3x its FY2024E/25E EPS estimates. We downgrade it to Hold from Buy with a revised PT of Rs. 5,100, using lower multiples than before to factor in uncertainty on impact of loss of exclusivity for gRevlimid’s 2.5 and 20.0 mg strengths on the profitability, going forward.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
